Jaypirca
pirtobrutinib
APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Launch2023-01-27
US LOE2036-01-01
Peak Sales Est$3000M
Formulations[{"id":"jaypirca-oral","doses":"200mg","route":"ORAL","setting":"PATIENT_SELF","duration":"Until pro
Mechanism: BTK inhibitor (non-covalent)
Expert: Non-covalent, reversible BTK inhibitor that maintains activity against C481S-mutant BTK, overcoming resistance to covalent BTK inhibitors like ibrutinib.
Everyday: Blocks a protein that B-cell cancers need to survive. Works even when other similar drugs stop working.
Targets: ["BTK"]
Revenue History
| Period | Revenue ($M) |
|---|
| Q3 2024 | $120M |
| 2024 | $400M |
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| CLL | PHASE3 | BRUIN CLL-321 | [{"stage":"PHASE3","region":"US"},{"stage":"PHASE3","region":"EU"}] |
| MCL | APPROVED | BRUIN | [{"stage":"APPROVED","region":"US","label_notes":"R/R after covalent BTK inhibit |
Upcoming Catalysts (2)
Pirtobrutinib - 1L MCL - FDA Filing
2026
Pirtobrutinib - CLL - Ph3 - Full Data vs Imbruvica
H1 2026
Notes
Pirtobrutinib, a highly selective non-covalent (reversible) BTK inhibitor for relapsed/refractory mantle cell lymphoma. First-in-class reversible BTK inhibitor, active against C481S resistance mutation that causes failure of covalent BTK inhibitors.
Data from Supabase · Updated 2026-03-24